SEAVI Advent Announces Investment in Leading TCM Provider, Shuang Yi Pharmaceutical and Biotech Holdings

May 2026

SEAVI Advent Private Equity today announced that its latest fund, SEAVI Advent VIII Fund has completed an investment in Shuang Yi Pharmaceutical and Biotech Holdings Ltd (the "Company"). The Company is a national high-tech enterprise specializing in the R&D, biotechnological extraction, standardization, and commercialization of Zhuang traditional medicines and botanical drug candidates. The Company has repeatedly been recognized as a National High-tech Enterprise and has been featured on China Central Television (CCTV) for five consecutive years for brand promotion. It is also recognized as an Enterprise Technology Center, Technology Innovation Demonstration Enterprise, and Specialized & New Enterprise by the Guangxi Zhuang Autonomous Region.

Founded in 1971 and headquartered in Laibin City—the "Capital of Zhuang Medicine" and a biodiversity hotspot for medicinal botanical resources—the Company operates seven dosage forms including granules, capsules, tablets, and syrups, with 42 product approvals. Among them, the "Compound Cold & Flu Granules" serves as the Company's strategic blockbuster product after a decade of focused development, holding a significant position in the cold medicine market. The Company concentrates on two major therapeutic areas: anti-cough/flu and anti-rheumatic Zhuang medicine therapies, both of which possess enormous market potential and are underpinned by proprietary biotechnological extraction processes.

Zhuang Medicine Biotechnology & Cold Medicine Market:

In 2024, the leading cold medicine brand already achieved a market size of RMB 10 billion. As a formula-upgraded biotech-enhanced product, the Company's Compound Cold & Flu Granules contains active ingredient concentrations higher than both national pharmacopoeia standards and market benchmarks, achieved through proprietary standardized extraction and quality control technologies. This offers significant differentiated competitive advantages. As one of only five approval holders nationwide and ranking first in this segment, the Company is poised to develop a billion-RMB blockbuster product while advancing the modernization and standardization of Zhuang ethnomedicine through biotech innovation.

Anti-Rheumatic Zhuang Medicine & Botanical Drug Pipeline:

The Company's exclusive flagship biotech product, "Shuangyi Qushi Tongluo Capsules", is the first product in China certified as a Zhuang patent medicine, holding national invention patents and offering unique ethnopharmacological efficacy in the treatment of rheumatic bone diseases. With accelerated population aging, increasing health awareness, and national policy support for the revitalization of ethnic minority medicines, market demand in this sector continues to grow. The Company is actively expanding its botanical drug R&D pipeline, leveraging biotechnological screening, molecular pharmacology, and modern formulation science to unlock the therapeutic potential of Guangxi's unique medicinal flora.

With over fifty years of deep cultivation in the Zhuang medicine and botanical drug sector, the Company has built an irreplicable competitive advantage at the intersection of ethnopharmacology and modern biotechnology. The Company combines the certainty of growth driven by blockbuster Zhuang medicine products with the expansion potential from its biotech R&D pipeline and standardized extraction platform, further benefiting from national policies promoting the revitalization of traditional Chinese medicine and the innovative development of ethnic minority medicines. SEAVI looks forward to partnering with the Company's team to support the Company's leapfrogging development from a regional Zhuang medicine leader to a national champion in ethnic medicine biotechnology.

About SEAVI Advent Private Equity

SEAVI Advent Private Equity, is one of the first private equity and venture capital firms to operate in the Asia Pacific region. Since 1984, the firm has invested over US$600 million into more than 120 Asian companies, from growth to late stage, as well as buyout and control transactions. With a proven track record that includes ranking fourth on Preqin’s Top 10 performance funds for its 2003/04 vintage, SEAVI Advent has been instrumental in delivering value to many of its portfolio companies, and has developed an extensive record of successful investments, which include Universal Health International Group (2211.HK), Hainan Shuangcheng Pharmaceutical Co. Ltd (002693.SZ), and Clarity Medical Group (1406.HK) in the healthcare sector; Weimob Inc. (2013.HK), Huitongda Network (9878.HK), and Sinofriends in the TMT sector; Tsaker New Energy (1986.HK), and Pengyao Group (300664.SZ) in the new energy & advanced manufacturing sector. SEAVI Advent VIII Fund focuses exclusively on investments in non-controlling public securities and profitable late-stage private companies.